In this article
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.
AstraZeneca stated its commitment to doubling its investment in its U.S. business shortly after Donald Trump’s election victory. The company revealed plans to allocate $2 billion towards research and development, increasing its total capital investment in the U.S. to $3.5 billion by 2026. This funding will be utilized to enhance research and development activities and expand manufacturing operations in the U.S.
The pharmaceutical giant anticipates that this new investment will lead to the creation of over 1,000 jobs, thereby contributing to the growth of the U.S. economy. AstraZeneca currently employs 17,800 individuals across 17 sites in 12 states in the U.S. The expanded footprint will include a research and development center in Cambridge, Mass., manufacturing facilities in Maryland and Texas, and additional sites on the West and East coasts.
This investment is part of AstraZeneca’s strategy to achieve its revenue target of $80 billion by 2030. The company is among the first major foreign corporations to announce increased investments in the U.S. following Trump’s reelection. While other companies made similar announcements during Trump’s first term, AstraZeneca did not explicitly attribute its decision to Trump’s reelection.
AstraZeneca’s CEO, Pascal Soriot, emphasized that the investment reflects the company’s confidence in the U.S. economy and marketplace for the coming years. The decision to expand investment in the U.S. has been under consideration for several months. The company’s motivation for the increased spending was initially linked to potential changes in President Joe Biden’s Inflation Reduction Act, but AstraZeneca later clarified that this was not the primary factor.
The acquisition of Summa Health by a subsidiary of General Catalyst for $485 million was announced on Thursday. This acquisition aims to eliminate $850 million in existing debt for Summa Health when combined with its current cash reserves. Summa Health operates across five counties in northeast Ohio and manages over 1,000 inpatient beds through its network of hospitals, health centers, and group practice.
General Catalyst’s creation of the Health Assurance Transformation Company (HATCo) laid the groundwork for the acquisition. HATCo plans to provide $350 million in capital funding to Summa over the first five years to invest in technology and support routine workflows. An additional $200 million will be allocated over the first seven years for strategic investments. The transition of Summa Health from a non-profit to a for-profit organization is part of the acquisition deal.
The acquisition is subject to regulatory approval, and representatives for General Catalyst and Summa Health have not yet responded to requests for comment. For more information on why HATCo is acquiring Summa, click here.
